NSABP FR-2

NSABP FR-2

A Phase II Study to Assess the Activity of PD-L 1 Inhibition with Durvalumab (MEDI4736) after Chemo-Radiotherapy in Patients with Stage II-IV Microsatellite Stable (MSS) Rectal Cancer

Protocol Chair: Thomas George, MD

Protocol Officer: Gene Finley, MD

Patient Population:
Patients with microsatellite stable (MSS) stage II-IV rectal cancer following standard chemo-radiotherapy

Target Accrual: 41 patients

Status: Not Recruiting

ClinicialTrials.gov Identifier: NCT03102407